Cronos Group Inc. Common Share (CRON) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Reported EPS
- $0.13
- Estimate
- $0.01
- Surprise
- +802.1%
- Revenue (period 2026-06-30)
- $53.0M
- Score at report (before → after)
- 5.8 → 6.5/10
Revenue source: xbrl.
How the report landed
Cronos Group Inc. Common Share (CRON) beat the $0.01 estimate with diluted EPS of $0.13 — a large 802.1% upside surprise. TrendMatrix's engine moved from Sell (5.8/10) to Buy (Wait) at 6.5/10 after the report.
Where TrendMatrix's rating stands now
TrendMatrix currently rates CRON Hold at 6.3/10.
2 of the last 4 quarters beat the estimate; this quarter's +802.1% surprise compares with a +461.5% four-quarter average. Next scheduled report: 2026-11-05.
What supports the rating
- Strong growth profile
- Outperforming peers
What argues against it
- Analyst target reached - limited upside remaining
- Near 52-week high (3.5% away)
- Target reached (-34.6% upside)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $3.28
- Price target
- $3.81
- Stop
- $3.08
- Upside to target
- +16.2%
Risk check: RSI 72 — a level conventionally read as overbought; gains at these levels often lean on momentum.
Model outputs from TrendMatrix’s engine as of 2026-08-23 — shown for context, not personalized investment advice.
CRON at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Drug Manufacturers - Specialty & Generic
- Market cap
- $1.22B
- P/E (fwd)
- -82.8
- P/E (ttm)
- 17.4
- 52-week range
- $2.28–$3.43
- Off 52-week high
- 4.4%
- RSI (14)
- 72
- Volume vs avg
- 0.88×
- Score today
- 6.3/10